Merus (NASDAQ:MRUS) PT Lowered to $30.00

Merus (NASDAQ:MRUSGet Rating) had its target price cut by Citigroup from $34.00 to $30.00 in a research report sent to investors on Wednesday morning, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. SVB Leerink reduced their price objective on Merus from $39.00 to $35.00 and set an outperform rating for the company in a research report on Friday, November 4th. Needham & Company LLC reduced their price objective on Merus from $40.00 to $28.00 and set a buy rating for the company in a research report on Friday, November 4th. StockNews.com started coverage on Merus in a research report on Wednesday, October 12th. They set a sell rating for the company. Stifel Nicolaus started coverage on Merus in a report on Tuesday, August 2nd. They set a buy rating and a $38.00 target price on the stock. Finally, HC Wainwright dropped their target price on Merus from $45.00 to $39.00 and set a buy rating on the stock in a report on Friday, November 4th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $37.29.

Merus Trading Down 4.2 %

NASDAQ:MRUS opened at $16.35 on Wednesday. Merus has a 1 year low of $12.03 and a 1 year high of $33.09. The stock has a market cap of $757.01 million, a price-to-earnings ratio of -11.43 and a beta of 0.91. The stock has a 50-day moving average price of $20.25 and a two-hundred day moving average price of $21.47.

Merus (NASDAQ:MRUSGet Rating) last posted its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.07. The company had revenue of $6.58 million during the quarter, compared to analysts’ expectations of $10.76 million. Merus had a negative return on equity of 20.48% and a negative net margin of 139.04%. Sell-side analysts forecast that Merus will post -1.97 earnings per share for the current year.

Insider Buying and Selling at Merus

In other Merus news, CEO Sven Ante Lundberg acquired 14,706 shares of the company’s stock in a transaction on Thursday, November 3rd. The shares were purchased at an average price of $14.38 per share, for a total transaction of $211,472.28. Following the completion of the purchase, the chief executive officer now directly owns 40,576 shares of the company’s stock, valued at $583,482.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Merus

Several institutional investors and hedge funds have recently bought and sold shares of MRUS. BNP Paribas Arbitrage SA increased its stake in shares of Merus by 107.4% during the second quarter. BNP Paribas Arbitrage SA now owns 1,811 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 938 shares during the period. Lazard Asset Management LLC bought a new position in shares of Merus during the first quarter worth approximately $58,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Merus by 53.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,825 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 989 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Merus by 330.5% during the third quarter. Tower Research Capital LLC TRC now owns 4,697 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 3,606 shares during the period. Finally, UBS Group AG increased its stake in shares of Merus by 278.1% during the first quarter. UBS Group AG now owns 3,732 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 2,745 shares during the period. Institutional investors own 76.36% of the company’s stock.

About Merus

(Get Rating)

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Further Reading

The Fly logo

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.